nmcv-5
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started Jun 10, 2019 (NCT03964012)
Timeline
Indications
Mechanism of action
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05093829 | Phase 3 | Feb 28, 2022 | Emory University, National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland |
| NCT04358731 | Phase 2/Phase 3 (Phase 3) | Dec 27, 2019 | Serum Institute of India Pvt. Ltd. |
| NCT03964012 | Phase 3 | Jun 10, 2019 | PATH, Serum Institute of India Pvt. Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Serum Institute of India Pvt. Ltd. | For profit | 2 | 2 | 1 | 2019 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2022 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1